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Abstract
Objectives. Depression and anxiety are associated with more severe disease in cross-sectional studies of axial
spondyloarthritis (axSpA). We examined the association between baseline symptoms of depression or anxiety and
response to TNF inhibitors (TNFi) in axSpA.
Methods. Biologic naı̈ve participants from a national axSpA register completed the Hospital Anxiety and
Depression Scale (HADS) before initiating TNFi. Symptoms of anxiety and depression were each categorized as
moderate–severe (11), mild (8–10) and ‘none’ (7), and compared against change in disease indices [BASDAI and
AS Disease Activity Score (ASDAS)] over time and time to treatment discontinuation using marginal structural mod-
els. Inverse-probability weights balanced baseline age, gender, BMI, deprivation, education and baseline values of
respective disease indices.
Results. Of the 742 participants (67% male, mean age 45 years), 176 (24%) had moderate–severe and 26% mild
depression; 295 (40%) had moderate–severe and 23% mild anxiety. Baseline disease activity was higher in higher
HADS symptom categories for both depression and anxiety. Participants with moderate–severe depression had sig-
nificantly poorer response compared with those with ‘none’ throughout follow-up. At 6 months, the difference was
approximately 2.2 BASDAI and 0.8 ASDAS units after balancing their baseline values. Equivalent comparisons for
anxiety were 1.7 BASDAI and 0.7 ASDAS units. Treatment discontinuation was 1.59-fold higher (hazard ratio 95%
CI: 1.12, 2.26) in participants with moderate–severe anxiety compared with ‘none’.
Conclusions. Symptoms of depression and anxiety at TNFi initiation are associated with poorer treatment out-
comes. Targeted interventions to optimize mental health have potential to substantially improve treatment response
and persistence.
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Introduction
Axial spondyloarthritis is characterized by severe inflam-
matory back pain and functional impairment. Symptom
onset is commonly in early adulthood, which can be a
Rheumatology key messages
. axSpA patients with moderate–severe depression have significantly poorer response to TNFi compared with
those with none.
. Moderate–severe anxiety is associated with 59% increased treatment discontinuation than those with none.
. Seventy-one per cent of participants with moderate–severe depressive symptoms did not have a documented
diagnosis of depression.
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critical time for education, career and relationships. The
consequence of these disruptive symptoms on mental
health is compounded by the often-significant delays to
diagnosis and treatment [1]. The burden of mental health
comorbidities is high, for example depression preva-
lence ranges from 15% to 38% depending on the
screening tool and population [2].
Mental health disorders are well-known to influence
the experience and reporting of symptoms [3]. This is
particularly relevant for assessment of axSpA disease
activity, since indices are mostly [e.g. AS Disease
Activity Score (ASDAS)] or entirely (BASDAI and spinal
pain) subjective. Prior studies have shown depression to
be consistently and independently associated with dis-
ease activity and other indices [2], yet none have exam-
ined whether they influence longitudinal treatment
outcomes. Unlike many other chronic comorbidities,
symptoms of depression and anxiety are potentially
modifiable, for example by pharmacological or talking
therapies [4]. Finding modifiable factors to improve TNFi
response is important as suboptimal response is
observed in up to half of treated patients [5], and the
number of therapeutic options remains relatively limited
compared with rheumatoid arthritis. Estimating the po-
tential impact of mental health interventions on TNFi re-
sponse will inform future clinical trials or management
guidelines.
Earlier exploratory analysis of the British Society for
Rheumatology Biologics Register for Ankylosing
Spondylitis (BSRBR-AS) identified, among others factors,
poorer mental health as a predictor of TNFi response [6].
Macfarlane et al. used stepwise selection of predictors to
show that, for each unit increase in the mental compo-
nent summary of the Short Form Health Survey-12 (SF-
12), odds of ASDAS clinically important response (reduc-
tion by 1.1) and ASDAS low disease activity (<2.1) were
significantly increased by 5%. Predictors do not neces-
sarily have a causal interpretation (e.g. stepwise variable
selection provides final models that may omit important
confounders [7, 8]), while SF-12 is a quality of life instru-
ment not validated to assess depression or anxiety.
Nevertheless, these findings suggested a need for more
detailed analysis, including a wider range of treatment re-
sponse definitions. Thus, we sought to examine the asso-
ciation between baseline symptoms of depression or
anxiety—using the Hospital Anxiety and Depression Scale
(HADS)—on response to TNFi. Specifically, we aimed to
estimate the potential benefits to treatment response—in
terms of absolute change in disease indices, binary re-
sponse criteria, and treatment discontinuation—if it were
possible to reduce symptoms of depression and anxiety
at or before TNFi initiation.
Methods
Patient population
The British Society for Rheumatology Biologics Register
for Ankylosing Spondylitis (BSRBR-AS) is a UK-wide
prospective cohort study that recruited biologics-naı̈ve
patients fulfilling the ASAS criteria for axial SpA between
December 2012 and December 2017 [9]. Biologics-naı̈ve
participants who started their first TNFi were eligible for
this analysis. They were followed up at baseline, 3, 6
and 12 months and annually thereafter. Eligible partici-
pants were required to have a baseline questionnaire,
including depression and anxiety symptoms, dated with-
in a window from 1 year before to 7 days after the TNFi
start date. This analysis used the study dataset of
December 2018. Ethical approval was obtained from the
National Research Ethics Service Committee (reference
11/NE/0374) and written informed consent was obtained
from all participants.
Depression and anxiety
Symptoms of depression and anxiety were measured
using the Hospital Anxiety and Depression Scale
(HADS). HADS comprises 14 questions, seven each for
the anxiety and depression subscores, to give each a
score ranging of 0 (none) to 21 (indicating severe symp-
toms). Its original description used each subscale to de-
scribe ‘case-ness’ with 0–7 indicating ‘non-cases’, 8–10
‘doubtful cases’, and 11 ‘cases’ [10, 11]. HADS de-
pression 8 was reported to have a sensitivity of 82%
and specificity of 74% for major depressive disorder
[12]. For HADS anxiety 8, sensitivity was reported as
90% and specificity 78% [13]. To categorize symptom
levels, we used 11 to indicate moderate to severe
symptoms and 8–10 mild. Snaith described the 0–7 cat-
egory as ‘being in the normal range’ [10]. For conveni-
ence, this category was referred to as ‘none’.
Outcomes
Response to TNFi was assessed using three comple-
mentary types of outcomes. First, we studied change in
(continuous) disease indices over follow-up time.
Disease activity was assessed using BASDAI, ASDAS
and the spinal pain numerical rating scale; other aspects
of disease severity and life impact were measured using
BASFI, AS quality of life questionnaire (ASQoL, which
has a range of 0–18 with higher scores indicating poorer
quality of life) and the Chalder Fatigue Scale, which has
a range of 0–33 with higher scores indicating greater lev-
els of fatigue [14]. To facilitate comparison of these indi-
ces with different ranges, we also standardized all to a
0–10 scale [i.e. (observed  minimum)/(maximum  min-
imum)  10]. Change in disease indices was assessed
over the first 3 years because few participants had lon-
ger follow-up.
We also examined common binary response defini-
tions at 6 months: BASDAI50/2 (50% or 2-unit reduc-
tion), ASDAS major improvement (ASDAS-MI, 2-unit
reduction), and two ‘low disease activity’ states
(BASDAI< 4 and ASDAS< 2.1). Individuals who
remained on drug but had a missing 6-month assess-
ment were considered as responders if they demon-
strated response at 3 or 12 months (participants were
unlikely to remain on drug if they did not have or lost
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response, as per UK prescribing guidelines [15]).
Participants who discontinued treatment within 6 months
for any reason were considered non-responders.
Lastly, we examined time to treatment discontinuation.
There were insufficient data to allow examination of
cause-specific discontinuation. Censoring was defined
by the last study contact (visit or questionnaire) for those
who did not discontinue.
Covariates
Covariates were determined a priori and supported by
direct acyclic graphs, including: age, gender, BMI, soci-
oeconomic status (Index of Multiple Deprivation [16] as
a continuous variable) and educational attainment (as
dummy variables). Baseline values of each disease index
were included in respective models.
Statistics
Descriptive statistics were used to compare participant
characteristics according to HADS categories. To esti-
mate group (rather than individual) level effects analo-
gous to those given by randomized trials, we used
marginal methods throughout [i.e. using inverse prob-
ability (IP) weights [17] rather than conditioning on cova-
riates]. The HADS 7 (‘none’) group was used as the
reference in all comparisons.
IP weighted generalized estimating equations were
used to assess for absolute change in disease activ-
ity. The model included each disease index in turn as
the dependent variable, and HADS-D category, time
and their interaction as the independent variable.
Time was modelled as linear splines with knots at 3
and 6 months based on known response trajectories
(i.e. improvement mostly occurs in the first 6 months
then plateaus thereafter). IP weighted logistic regres-
sion was used for binary response definitions. IP
weighted pooled logistic regression (i.e. marginal
structural Cox models) was used for time-to-
treatment discontinuation, with time modelled in
quadratic form. We further relaxed proportional haz-
ards assumptions with time-by-exposure interactions.
Each of these models was then repeated for HADS-A
categories. Missing follow-up data (proportion shown
in Supplementary Data, available at Rheumatology on-
line) were not imputed.
IP weights balance all covariates in the weighted model
to allow unconfounded descriptive comparisons [12]. The
numerator was the predicted probability from a multi-
nomial logistic model with three-level categorical HADS
as the only variable, and the denominator was the same
model conditioned on all covariates. Additional details on
derivation of IP weights are shown in Supplementary
Data, available at Rheumatology online.
Sensitivity analyses
Participants with baseline BASDAI< 4 would not ordinar-
ily be eligible for TNFi according to UK prescribing guid-
ance. These individuals were excluded in the first set of
sensitivity analyses. Using the above definitions of binary
response, individuals who stayed on treatment but did
not have assessments recorded at 3, 6 or 12 months
would have missing response values. In the second sen-
sitivity analysis, these individuals were assumed to have
responded at 6 months if they remained on treatment
beyond 1 year. Third, adequate overlap in participant
characteristics between HADS groups is required for
valid causal inference, for which we used a weighting
analogue of propensity score matching [18].
Results
Among 2687 participants in the BSRBR-AS, 1145
started on biologics; 742 completed the HADS and were
eligible for this analysis (flow chart in Supplementary Fig.
S1, available at Rheumatology online). TNFi initiators
included and excluded from the analysis set were similar
in characteristics except the former were older (45 vs
43 years) (see Supplementary Table S1). The analysis
cohort was predominantly (67%) male with a mean age
of 45 years.
Participants in each category of depressive symptoms
were similar in age and gender (Table 1). Those with no
depression had lower BMI and higher educational attain-
ment than mild to severe. Anxiety severity was associ-
ated with younger mean age, but not BMI or education
(Table 2). More severe symptoms of depression and
anxiety were each associated with greater deprivation,
disease activity, fatigue and impairment to function and
quality of life.
Only 29% of those with moderate–severe depressive
symptoms had a documented depression diagnosis
(Table 1). HADS depression and anxiety subscores were
highly correlated (Supplementary Fig. S2 and Table S2,
available at Rheumatology online).
Absolute improvement in continuous outcomes
All baseline covariates were adequately balanced
(Supplementary Fig. S3, available at Rheumatology on-
line); IP weights are described in Supplementary Table
S3 . The number of individuals included for analysis
ranged from 673 to 741 depending on missing outcome
data (Supplementary Table S4). Those with ‘no’ depres-
sive symptoms had superior TNFi response across all
six indices, compared with with mild or moderate–severe
groups. For example, those with ‘no’ depressive symp-
toms had approximately 2.2 units greater response in
BASDAI, 0.8 units in ASDAS, and 2.3 units in spinal pain
at 6 months than the moderate–severe depression group
(Fig. 1). This persisted throughout follow-up.
Improvement in quality of life was slow, unlike other indi-
ces that showed sharp improvements after TNFi
initiation.
Results were similar for anxiety categories (Fig. 2).
At 6 months, response in moderate–severe and ‘none’
groups differed by 1.7 BASDAI units, 0.7 ASDAS and 1.7
spinal pain (full model coefficients and predicted values
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TABLE 1 Baseline characteristics compared according to depression symptom categories
‘None’ (n 5 374) Mild (n 5 192) Moderate–severe (n 5 176) P-value
Age, mean (S.D.), years 45.3 (14.6) 45.5 (13.6) 45.5 (12.8) 0.97
Males, n (%) 248 (66) 133 (69) 115 (65) 0.69
Meeting modified New York criteria, n (%) 221 (59) 118 (61) 96 (55) 0.40
Age at symptom onset, mean (S.D.), years 28.0 (10.7) 29.5 (12.2) 29.4 (12.3) 0.21
Symptom duration, mean (S.D.), years 17.3 (13.4) 16.0 (12.5) 16.1 (13.1) 0.43
HLA-B27 positive, n (%) 218 (78) 106 (75) 90 (70) 0.23
BMI, mean (S.D.), kg/m2 27.2 (5.2) 29.0 (6.1) 28.8 (6.5) 0.002
Education, n (%)
Secondary school 107 (29) 71 (37) 22 (50) 0.006
Apprenticeship 36 (10) 16 (8) 4 (9)
Further education college 110 (29) 62 (33) 15 (34)
University degree 93 (25) 34 (18) 2 (5)
Further degree 28 (7) 7 (4) 1 (2)
IMD, mean (S.D.) 2.9 (1.4) 3.1 (1.4) 3.3 (1.4) 0.004
NSAID use in past 6 months, n (%) 277 (75) 138 (74) 123 (71) 0.62
DMARD use in past 6 months, n (%) 44 (12) 25 (14) 38 (22) 0.009
ASDAS, mean (S.D.) 2.6 (0.8) 3.1 (0.7) 3.3 (0.7) <0.001
BASDAI, median (IQR) 6.0 (4.5, 7.2) 7.0 (6.0, 7.8) 7.7 (6.9, 8.9) <0.001
Spinal pain, median (IQR) 6.0 (4.0, 7.0) 7.0 (6.0, 8.0) 8.0 (6.0, 9.0) <0.001
BASFI, median (IQR) 5.4 (3.3, 7.0) 6.9 (5.4, 8.3) 8.1 (6.8, 9.1) <0.001
ASQoL, median (IQR) 10.0 (7.0, 13.0) 14.0 (12.0, 16.0) 16.0 (14.0, 17.0) <0.001
Fatiguea, median (IQR) 15.0 (12.0, 19.0) 18.0 (16.0, 22.0) 22.0 (18.0, 26.5) <0.001
History of physician diagnosed depression, n (%) 31 (8) 31 (16) 51 (29) <0.001
aThe Chalder Fatigue Scale ranges from 0 (low) to 33 (high). ASDAS: AS disease activity score; ASQoL: AS quality of life
questionnaire; BASDAI: Bath AS disease activity index; BASFI: Bath AS functional index; IMD: index of multiple deprivation
with 1 (least deprived) to 5 (most); IQR: interquartile range.
TABLE 2 Baseline characteristics compared according to anxiety symptom categories
None (n 5 278) Mild (n 5 169) Moderate–severe (n 5 295) P-value
Age, mean (S.D.), years 47.0 (14.7) 45.5 (13.9) 43.8 (13.0) 0.022
Males, n (%) 188 (68) 120 (71) 188 (64) 0.27
Meeting modified New York criteria, n (%) 165 (59) 106 (63) 164 (56) 0.32
Age at symptom onset, mean (S.D.), years 28.3 (11.6) 29.3 (11.1) 28.8 (11.8) 0.66
Symptom duration, mean (S.D.), years 18.7 (13.4) 16.2 (13.1) 15.0 (12.5) 0.003
HLA-B27 positive, n (%) 174 (81) 83 (70) 157 (73) 0.047
BMI, mean (S.D.), kg/m2 27.8 (5.5) 27.8 (5.1) 28.5 (6.4) 0.39
Education, n (%)
Secondary school 89 (32) 60 (36) 102 (35) 0.067
Apprenticeship 29 (10) 14 (8) 27 (9)
Further education college 81 (29) 42 (25) 104 (36)
University degree 62 (22) 45 (27) 42 (14)
Further degree 16 (6) 8 (5) 15 (5)
IMD, mean (S.D.) 2.8 (1.4) 3.0 (1.3) 3.2 (1.4) 0.011
NSAID use in past 6 months, n (%) 205 (75) 125 (75) 208 (72) 0.56
DMARD use in past 6 months, n (%) 43 (16) 18 (11) 46 (16) 0.30
ASDAS, mean (S.D.) 2.6 (0.9) 2.9 (0.7) 3.1 (0.8) <0.001
BASDAI, median (IQR) 5.9 (4.4, 7.2) 6.6 (5.5, 7.4) 7.4 (6.2, 8.5) <0.001
Spinal pain, median (IQR) 6.0 (4.0, 8.0) 7.0 (5.0, 8.0) 7.0 (6.0, 8.0) <0.001
BASFI, median (IQR) 5.6 (3.3, 7.1) 6.3 (4.6, 8.1) 7.2 (5.7, 8.6) <0.001
ASQoL, median (IQR) 10.0 (6.0, 13.0) 12.0 (10.0, 15.0) 15.0 (12.0, 17.0) <0.001
Fatiguea, median (IQR) 15.0 (12.0, 19.0) 17.0 (14.0, 21.0) 20.0 (17.0, 24.0) <0.001
aThe Chalder Fatigue Scale ranges from 0 (low) to 33 (high). ASDAS: AS disease activity score; ASQoL: AS quality of life
questionnaire; BASDAI: Bath AS disease activity index; BASFI: Bath AS functional index; IMD: index of multiple deprivation
with 1 (least deprived) to 5 (most); IQR: interquartile range.
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are shown in online Supplementary Tables S4–S7, avail-
able at Rheumatology online). All effect sizes were numer-
ically smaller than the above comparisons for depression.
For both depression and anxiety, difference between
‘none’ and moderate–severe groups was largest for
ASQoL (standardized scales shown in Supplementary
Figs S4 and S5).
Binary treatment response
The number of individuals included for analysis was 542
for BASDAI-based and 492 for ASDAS-based outcomes.
BASDAI50/2 was achieved by 304 (56%), BASDAI< 4 by
308 (57%), ASDAS-MI by 129 (26%) and ASDAS< 2.1
by 167 (34%). Odds of achieving binary response
reduced with increasing severity of baseline depression
symptoms (Fig. 3). Compared with those with ‘no’ de-
pression, participants with moderate–severe symptoms
had around half the odds of achieving response at
6 months after accounting for all covariates including dif-
ferences in baseline BASDAS or ASDAS. Groups with
mild depression had 39–48% lower odds of response.
Treatment discontinuation
Analyses included 742 patients and 1036 person-years of
follow-up, with median of 12 (interquartile range 5–25)
months. Very few individuals had follow-up beyond
4 years. Thirty-one per cent of the cohort stopped treat-
ment over the study; 26% of participants in the ‘none’
group for depression discontinued, 35% in mild and 38%
in the moderate–severe group; 25% in the ‘none’ group
for anxiety discontinued, 31% in mild and 37% in the
moderate–severe anxiety group. Drug survival according
to HADS symptom categories are shown in Fig. 4.
In marginal structural Cox models, symptoms of de-
pression or anxiety were associated with greater hazard
of treatment discontinuation (i.e. greater number of indi-
viduals discontinued at any one time, assuming rates
are proportional). Compared with those with ‘no’ depres-
sion, the mild group had 32% higher (95% CI: 0.93,
1.87), and the moderate–severe group 45% higher (95%
CI: 0.99, 2.12), hazard rate of treatment discontinuation.
Compared with those with ‘no’ anxiety, the group with
mild anxiety at baseline had 36% higher (95% CI: 0.91,
2.05), and the moderate–severe group 59% higher (95%
CI: 1.12, 2.26), hazard of TNFi discontinuation.
Kaplan–Meier estimators suggested potential violation
of the proportional hazards assumption. Comparison be-
tween none and moderate–severe groups was approxi-
mately proportional, as shown by marginal structural Cox




































































Full model output and marginal predictions are shown in Supplementary Tables S4 and S5, available at Rheumatology
online. ASDAS: AS disease activity score; ASQoL: AS quality of life questionnaire; BASDAI: Bath AS disease activity
index; BASFI: Bath AS functional index.
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Full model output and marginal predictions are shown in Supplementary Tables S6 and S7, available at Rheumatology
online. ASDAS: AS disease activity score; ASQoL: AS quality of life questionnaire; BASDAI: Bath AS disease activity
index; BASFI: Bath AS functional index.





























































































































Full model output shown in Supplementary Table S8, available at Rheumatology online. ASDAS: AS disease activity
score; BASDAI: Bath AS disease activity index; HADS: Hospital Anxiety and Depression Scale; MI: major
improvement.
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models using flexible baseline hazards (Supplementary
Fig. S6, available at Rheumatology online).
Sensitivity analyses
Analyses excluding participants with baseline BASDAI< 4,
imputing response at 6months for participants who remained
on treatment beyond one year and using matching weights
to improve covariate overlap (thus causal inference) did not
yield meaningfully different results (data not shown).
Discussion
In this large national cohort, axSpA patients with mild to
severe symptoms of depression or anxiety had markedly
poorer response to their first TNFi compared with those
with less than mild symptoms. Interventions to optimize
mental health at or before TNFi initiation may dramatical-
ly improve treatment response.
A key strength of this study is its large sample size,
recruited from a broad range of rheumatology centres.
We used three response definitions that each lend
unique strengths to the overall conclusion. Diagnoses
correlate poorly with dynamic and often under-
recognized symptoms; therefore studying symptoms of
depression/anxiety, rather than documented diagnosis,
provides effect estimates that have greater relevance to
clinical practice and potential interventions. There were
also limitations. Studying the causal effect of baseline
mental health symptoms (a ‘prevalent exposure’) has
conceptual difficulty; the implied hypothetical interven-
tion would need to successfully improve baseline symp-
toms, but also symptoms pre-baseline of unknown
duration. This might be considered as an intervention
administered before (rather than at) TNFi initiation, but
true causal effect sizes are likely smaller. Even if more
realistic effect estimates were half the size, they still re-
main larger and more amenable to intervention that
other ‘modifiable risk factors’: smoking status does not
convincingly impact treatment outcomes [19]; and BMI
is associated with treatment outcomes [20] but causal
effects are conceptually problematic to estimate and
intervention practically difficult to implement [21].
Categorizing HADS subscores will have reduced statis-
tical power. Using IP weights for continuous HADS
requires strong assumptions of its distribution; it would
also assume a linear relationship between HADS and
treatment outcomes, which the above results showed
not to hold. Results from weighted generalized estimat-
ing equations should be interpreted with the limitation
that participants who did not respond by the first as-
sessment (usually after 3 months) or those who lost re-
sponse would have had their treatment stopped under
NICE guidance; therefore, record of such high disease
activity would be censored. This informative censoring
should not affect data within the first 3 months. Our
results may be affected by unmeasured confounders
(e.g. illness beliefs or attitudes to health). To estimate
the potential effect of unmeasured confounding, take for
example the comparison of 6-month BASDAI50/2 re-
sponse between moderate–severe depression vs ‘none’
(odds ratio 0.51) and treatment discontinuation between
moderate–severe anxiety vs ‘none’ (hazard ratio 1.59).
These point estimates could be explained away by an
unmeasured confounder that was associated with both
the exposure and outcome by over 2-fold each, above
and beyond measured confounders; weaker confound-
ing could not do so [22]. An unmeasured confounder of
this effect size is unlikely.
Mental health disorders are under-recognized and
underdiagnosed in axSpA, despite their high prevalence
and association with many other important health factors
such as alcohol/drug abuse and suicide [23]. In this
data, 71% of participants with HADS subscores 8
(which has high sensitivity and specificity for respective
disorders, see Methods) did not have a documented
diagnosis. Mental health symptoms are dynamic and
should be assessed as such in routine clinical practice.
Numerous cross-sectional studies have shown higher
disease activity in axSpA patients with depression [2]. To
FIG. 4 Kaplan–Meier curves comparing drug survival be-
tween participant groups with different categories of
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HADS: Hospital Anxiety and Depression Scale.
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our knowledge, only one prior study—which used an
early version of the same BSRBR-AS dataset—described
mental health (using SF-12) as part of overall predictors
of treatment response in axSpA [6]. By contrast, the cur-
rent analysis was designed to provide improved causal
interpretation, and extended outcome measures beyond
binary definitions. Binary definitions have inherent limita-
tions when using observational data [24]; for example,
high baseline DAS28 is a predictor that simultaneously
increases odds of ACR70 response and decreases odds
of DAS remission in RA [25]. The current analysis using
HADS also has advantages. Unlike the SF-12, HADS is a
validated tool to assess depression and anxiety, and
excludes questions relating to somatic symptoms that
may be confounded by concurrent axSpA. HADS is also
an easier tool to adopt into clinical practice as it is free
and its scores are easier to calculate.
Results of the current analysis are consistent with stud-
ies in RA, where symptoms of depression (measured
using the SF-36) were associated with reduced good
EULAR response [26]. The authors used mixed models to
examined linear improvement through months 6 and 12,
showing an adjusted difference in DAS28 of 0.01 units
between those with and without depression symptoms.
This and related effect sizes were orders of magnitude
smaller than that deemed clinically meaningful. Contrast
this to a difference of 2.2 BASDAI units and 0.8 ASDAS
units between axSpA patients with moderate–severe and
‘no’ depression (clinically meaningful differences are
around 1 unit for BASDAI and ASDAS [27]). This may be
explained by limitations of SF-36 for assessing mental
health or the uniquely subjective ways in which axSpA
disease activity is assessed. Depression is known to influ-
ence the experience and reporting of symptoms [3],
which is supported by larger effect sizes for BASDAI than
(the more objective) ASDAS.
This study is also the first to assess the impact of anx-
iety on treatment outcomes. Anxiety is often assumed to
exist in parallel with depression and thus overlooked in
clinical practice and research. Although correlated, the
two symptoms are not equivalent. Of those without de-
pressive symptoms, nearly half had at least mild symp-
toms of anxiety and 1 in 5 had at least moderate.
Conversely, 22% of those without anxiety had at least
mild symptoms of depression (Supplementary Table S2,
available at Rheumatology online). Baseline anxiety symp-
toms were significantly associated with treatment discon-
tinuation, with effect sizes larger than equivalent analyses
for depression. Assuming a valid causal model, reducing
moderate–severe symptoms of anxiety may significantly
improve treatment persistence.
These results suggest that symptoms of both depres-
sion and anxiety should be systematically screened in
routine practice. This allows clinicians to predict treat-
ment response better, but more importantly to highlight
individuals who may benefit from mental health interven-
tions. Approximately half of axSpA patients do not re-
spond adequately to their first TNFi [5]. Optimizing
mental health may offer substantial improvements in
axSpA treatment response. Conversely, neglecting men-
tal health may lead those with severe mental health
symptoms to ‘double jeopardy’, where apparent inad-
equate response in disease indices means their TNFi are
withdrawn in healthcare systems like the UK.
Randomized controlled trials of mental health interven-
tions in axSpA (and indeed all chronic rheumatic dis-
ease) are needed. The number of pharmacological
options is increasing but as yet not reliably effective in
routine practice, while talking therapies are difficult to
access. Improving access to the latter, for example
using internet or telephone delivered cognitive behav-
ioural therapy, may be one solution.
In conclusion, symptoms of depression and anxiety at
TNFi initiation were each associated with adverse treat-
ment outcomes. Assuming that marginal models provide
an adequate approximation of real causal effects, reduc-
ing moderate–severe symptoms of depression to less
than mild at TNFi initiation may improve absolute re-
sponse by approximately 2 BASDAI and 1 ASDAS units,
and binary response definitions by around 2-fold.
Similarly, improving anxiety symptoms may reduce treat-
ment discontinuation by up to a third. These findings
highlight the importance of routinely screening and opti-
mizing depression and anxiety in routine clinical practice.
Randomized controlled trials are needed to identify effi-
cacious mental health interventions for axSpA patients.
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